# Apimeds Pharmaceuticals US, Inc (APUS)

> Healthcare · US · Reports in USD

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/APUS/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | $ 0 | $ -55.23M | $ -8.33M | $ 14.58M | $ 106.45M |
| 2025 | $ 0 | $ -6.14M | $ -9.20M | $ 7.76M | $ 153.35M |
| 2024 | $ 0 | $ -1.46M | $ -771.0K | $ 596.8K | $ -1.36M |
| 2023 | $ 0 | $ -840.9K | $ -678.8K | $ 266.9K | $ 31.9K |
| 2022 | $ 0 | $ -83.3K | $ -22.3K | $ 660.0K | $ -713.6K |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.14 |
| Liabilities / Eq | 0.20 |
| Current Ratio | 0.51 |

## Other views

- [Metrics](https://sponda.capital/en/APUS.md)
- [Charts](https://sponda.capital/en/APUS/charts.md)
- [Compare](https://sponda.capital/en/APUS/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-29.